Which vertebral level should be used to calculate sarcopenia in covid-19 patients? A systematic review and meta-analysis

Abstract

Evidence shows that CT-derived sarcopenia can predict adverse outcomes in COVID-19 patients. However, discrepancies exist as to which vertebral level can be used to calculate sarcopenia which can effectively serve as a prognostic tool. Thus, we aim to investigate the difference in sarcopenia calculated at the Thoracic and Lumbar vertebral levels. An online literature search was conducted on Electronic databases such as PubMed, Cochrane CENTRAL, and Google scholar. Meta-analysis was performed by using Revman 5.3 software. A total of 14 articles were selected for meta-analysis. The prevalence of sarcopenia calculated at the Thoracic level was 31% (95%CI 24%-37%; p<0.00001; I2=86%), while sarcopenia calculated at the Lumbar vertebral level was 63% (95%CI 51%-75%; p<0.00001; I2=88%). Meanwhile, sarcopenia calculated at the Upper thoracic level was a significant predictor of mortality OR 3.47 (95%CI 1.74-6.91; p=0.0004; I2=56%)as compared to sarcopenia calculated at the lower thoracic OR 1.74 (95%Cl 0.91-3.33; p=0.10; I2=60%)or lumbar level OR 2.49 (95%CI 0.45-13.72; p=0.30; I2=57%). In addition to this sarcopenia calculated at the Upper thoracic level was also a significant predictor of severe illness OR 3.92 (95%CI 2.33-6.58; p<0.00001; I2=0%) as compared to lower thoracic OR 1.40 (95%CI 0.78-2.53; p=0.26; I2=67%) or lumbar level OR 1.64 (95%CI 0.26-10.50; p=0.60; I2=81%) CONCLUSIONS: Sarcopenia calculated at the thoracic vertebrae and lumber level has different prognostic values. Sarcopenia is prevalent at the lumbar level. Sarcopenia at the thoracic level has a higher mortality and severity rate.